#UK #Haverhill #Codis #ASDs #GEA PSD4

Codis' Major Investment in Spray Drying Technology

Codis, a leading global contract development and manufacturing organization (CDMO) known for its expertise in spray drying and amorphous solid dispersions (ASDs), has recently announced a significant expansion in its manufacturing capabilities. This move marks a pivotal milestone in the company's commitment to enhancing the availability and production of bioavailability-enhanced medicines.

Investment Overview

On March 4, 2026, Codis revealed its plans to purchase a GEA Pharma-SD® type PSD-4 solvent-capable spray dryer, making it the only CDMO in the UK to offer this advanced capacity. This new technology will be installed at Codis’ 400,000 square-foot facility located in Haverhill, UK, with operations expected to commence in 2027. The investment is backed by the UK government's Life Sciences Innovative Manufacturing Fund (LSIMF), providing vital support to bolster local life sciences manufacturing.

The GEA PSD4 is designed for large-scale, cGMP pharmaceutical applications, capable of producing commercial batches of up to 500 kg, with a total capacity reaching 30,000 kg annually. This advanced equipment is specifically aimed at meeting the increasing demand for solvent-based spray drying, a process that plays a crucial role in enhancing the bioavailability of poorly soluble drug candidates.

Enhancing Customer Capabilities

With this new addition, Codis aims to provide its customers with an efficient and streamlined path from the development phase to full-scale commercial manufacturing of ASDs. Codis' existing platform already includes a PSD2 unit, which accommodates pilot-scale and smaller commercial production. The combination of these facilities will offer clients a comprehensive service, ensuring that they can bring their innovative drug formulations to market more swiftly and effectively.

"This investment marks a vital step forward in Codis' growth as a global leader in the spray drying industry and the manufacturing of ASDs," stated Nicolas Fortin, CEO of Codis. "The PSD4 significantly enhances our production capacity and allows our clients to rapidly bring life-altering medications to market. We appreciate the support from the UK government through the LSIMF, which enables us to fast-track this project and further invest in our Haverhill site."

Economic Impact

The construction and installation of the PSD4 equipment are expected to create temporary job opportunities in the Haverhill community, with the potential for long-term positions as production scales up. Codis plans to engage local suppliers, contractors, and service providers, thereby contributing to the ongoing economic development of the life sciences sector in the region.

About Codis

Codis is a renowned CDMO that excels in large-scale spray drying, amorphous solid dispersions, particle engineering, and finished-dose manufacturing across the pharmaceutical, consumer health, nutraceutical, and OTC sectors. With cGMP facilities in locations such as St. Louis, Missouri, Seymour, Indiana, and Haverhill, UK, Codis leverages decades of regulatory expertise and operational excellence to drive success. To learn more about their offerings, visit Codis Website.

In summary, Codis' latest investment in the GEA PSD4 solvent spray dryer not only enhances its capabilities but also reinforces its mission to enable clients to innovate and deliver effective healthcare solutions. The emphasis on local economic growth and job creation aligns seamlessly with Codis' commitment to advancing life sciences, demonstrating the importance of collaborative efforts in driving progress within the industry.